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ABSTRACT: The aim of the present study was to improve the immunogenicity of peptide epitope vaccines using novel
nanocarriers based on self-assembling materials. Several studies demonstrated that peptide antigens in nanoparticulate form
induce stronger immune responses than their soluble forms. However, several issues such as poor loading and risk of inducing T
cell anergy due to premature release of antigenic epitopes have challenged the clinical success of such systems. In the present
study, we developed two vaccine delivery systems by appending a self-assembling peptide (Ac-AAVVLLLW-COOH) or a
thermosensitive polymer poly(N-isopropylacrylamide (pNIPAm) to the N-terminus of different peptide antigens (OVA250−264,
HPV-E743−57) to generate self-assembling peptide epitopes (SAPEs). The obtained results showed that the SAPEs were able to
form nanostructures with a diameter from 20 to 200 nm. The SAPEs adjuvanted with CpG induced and expanded antigen-
specific CD8+ T cells in mice. Furthermore, tumor-bearing mice vaccinated with SAPEs harboring the HPV E743−57 peptide
showed a delayed tumor growth and an increased survival compared to sham-treated mice. In conclusion, self-assembling peptide
based systems increase the immunogenicity of peptide epitope vaccines and therefore warrants further development toward
clinical use.
KEYWORDS: therapeutic cancer vaccine, immunotherapy, human papillomavirus (HPV), ovalbumin (OVA),
self-assembling peptide epitopes, nanoparticles
1. INTRODUCTION
Utilizing the patient’s immune system represents a promising
approach for eradication of cancer.1,2 The immune system is
well equipped to identify and eliminate malignant cells, but
cancer cells can escape from immune surveillance, which can
lead to the development of tumors with the potential to
metastasize.3,4 Cancer vaccines aim to evoke a strong adaptive
immune response against tumor antigens,5−7 and among many
different strategies applied in recent years, synthetic peptide
epitopes have been an important approach for T cell based
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immunotherapy of cancer.8 However, unsatisfactory antitumor
effects in both animal models and humans have raised the
question whether these peptide epitopes, even in combination
with strong adjuvants, are sufficiently immunogenic.9−11
Insufficient efficiency of minimal peptide-based vaccines may
be due to their rapid extracellular degradation, fast diffusion
from the site of injection and poor uptake by antigen-
presenting cells, including dendritic cells (DCs), as well as
lack of generation of costimulatory signals.12,13 In some
publications, short peptide vaccines have been reported to
induce T-cell tolerance and anergy by direct binding to major
histocompatibility complex (MHC) molecules on all cells,
instead of only antigen presenting cells.14,15 Therefore,
synthetic long peptides (SLPs) have been proposed as a
solution of these drawbacks of the minimal peptide epitope
vaccines.16 However, SLPs are still prone to enzymatic
degradation by proteases present in blood and also by
endopeptidases and exopeptidases present on the surface of
DCs.16 Moreover, due to their relatively small size, these
peptide vaccines are rapidly cleared from the injection site, and
as a consequence, their uptake by DCs is limited.17,18
Furthermore, lack of information on pharmacokinetic and
physical properties (solubility/aggregation) of peptide vaccines
impedes control and prediction of immune responses.12
Numerous studies have demonstrated that delivery of peptide
vaccines through particulate carriers (e.g., polymeric or lipidic
nanostructures) can improve the efficacy of peptide epitopes
through, for example, protection against degradation and better
uptake by DCs.19−24
Self-assembling peptides have gained increasing attention as a
way to construct biomaterials for biomedical applications such
as scaffolds for tissue engineering or nanomaterials for drug and
vaccine delivery.25 Self-assembling peptides can be synthesized
by both standardized solid phase peptide synthesis methods
and recombinant technology.26,27 Furthermore, these peptides
are easy to formulate since simple dispersion in aqueous media
results in the spontaneous formation of discrete and uniform
particles, without the need for laborious processing as often the
case for other particulate systems.28,29 Furthermore, other
functionalities such as adjuvanticity and receptor/cell specificity
can be introduced in a single polypeptide.25 In the present
study, we have designed short amphiphilic peptides (SA2 and
SA7: Ac-AAVVLLLWE2−7-COOH) that form nanovesicular
structures in aqueous solution.30 The self-assembly was due to
both hydrophobic clustering and intermolecular hydrogen bond
formation as driving forces.26,28
Progress in polymer science has resulted in a variety of
polymers suitable for drug delivery applications.31 Particularly,
stimuli-responsive polymers that respond to certain stimuli
such as pH, temperature, light, magnetism, or ultrasound have
received tremendous interest in the last decades.32 As an
example, poly(N-isopropylacrylamide) (pNIPAm), is hydro-
philic and water-soluble below the so-called lower critical
solution temperature (LCST), whereas above this temperature
of ∼33 °C it is insoluble in water and precipitates. Because of
this thermoreversible behavior pNIPAm has been used in
triggerable drug delivery systems.34,33
The aim of this study was to augment the immunogenicity of
peptide epitopes by conjugating them to self-assembling
moieties to obtain well-defined nanostructures for cancer
immunotherapy. In the present study, the OVA250−264 peptide
(SGLEQLESIINFEKL (covering a CD8+ epitope of ovalbu-
min: SIINFEKL)) and the HPV16 E743−57 of the E7 protein of
human papillomavirus type 16 (GQAEPDRAHYNIVTF
(covering both a CD8+ epitope RAHYNIVTF and a CD4+
epitope PDRAHYNI)) were conjugated to the hydrophobic
domain of the SA2 peptide (Ac-AAVVLLLW-COOH) or to
the thermosensitive polymer (pNIPAm) to trigger peptide self-
assembly into discrete nanostructures. The peptide vaccines
were biophysically characterized, and their capacity to induce or
expand antigen-specific CD8+ T cell were tested in mice.
Finally, in vivo studies in mice were conducted to evaluate the
efficacy of SAPEs that contain the HPV peptide epitope (HPV
SAPEs) as a therapeutic vaccine.
2. EXPERIMENTAL SECTION
2.1. Materials. Acetonitrile (ACN), dichloromethane
(DCM), dimethylformamide (DMF), methyl-tert-butyl ether
(MTBE), N-methyl-2-pyrrolidine (NMP), n-hexane, and
diethyl ether were purchased from Biosolve BV (Valkenswaard,
The Netherlands). N-Isopropylacrylamide (NIPAm; >99%),
N,N-dimethyl acrylamide (DMAm; >99%), deuterium oxide
(D2O), deuterated dimethyl sulfoxide, (99.9%, DMSO-d6), α-
bromoisobutyryl bromide, triisopropylsilan, Nile red, poly-L-
lysine, hexafluoroisopropanol (HFIP), and 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES) were purchased
from Sigma-Aldrich (Zwijndrecht, The Netherlands). Sodium
hydroxide and HCL were bought from Merck (Darmstadt,
Germany). N,N-Diisopropyl-ethylamine (DIPEA) was pur-
chased from Biosolve (Valkenswaard, The Netherlands).
CuCl and CuCl2 were obtained from Sigma-Aldrich (Zwijn-
drecht, The Netherlands). Phosphate-buffered saline (NaCl, 8.2
g/L; Na2HPO4·12H2O, 3.1 g/L; NaH2PO4·2H2O, 0.3 g/L)
(PBS) was purchased from B. Braun (Melsungen, Germany).
Iscove’s Modified Dulbecco’s Medium (IMDM) was purchased
from Lonza (Walkersville, USA). CPG ODN 1826 (CpG) was
purchased from InvivoGen (Cayla, France). Tris(2-
dimethylaminoethyl)amine (Me6TREN) was prepared accord-
ing to a reported procedure.34 PE-labeled H-2Db epitope
E749−57 (RAHYNIVTF)- and PE-labeled H-2D
b epitope
OVA257−264 (SIINFEKL)-containing tetramers were con-
structed and used for the analysis of peptide-specific CTL




OVA250−264 (OVA) NH2-SGLEQLESIINFEKL-COOH (SIINFEKL is a CTL epitope of ovalbumin) 1719.95 Ansynth Service BV (Roosendaal,
Netherlands)
HPV16 E743−57 (HPV) NH2-GQAEPDRAHYNIVTF-COOH (RAHYNIVTF is CTL epitope, and
DRAHYNI is a Th epitope of HPV E7)




Ac-AAVVLLLWSGLEQLESIINFEKL-COOH 2628.11 Genscript (New Jersey, USA)
HPV-SA (contains: HPV16
E743−57)
Ac-AAVVLLLWGQAEPDRAHYNIVTF-COOH 2626.01 Selleck Chemicals (Houston, TX)
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immunity as described earlier.35 All other chemicals were of
analytical grade, and all aqueous solutions were prepared with
Millipore Milli-Q deionized water (18.2 MΩ; Millipore Milli-Q
system, Billerica, MA). HEPA vent filters were obtained from
Whatman (Kent, U.K.).
Resin-protected peptide epitopes of ovalbumin (OVA250−264:
DEVSGLEQLESIINFEKL) and human papilloma virus type 16
(HPV 16) oncoprotein E7 (HPV16-E743−57: GQAEPDRAHY-
NIVTF) were ordered from Ansynth Service BV (Roosendaal,
Netherlands). The purity of the mentioned peptides as
determined by reverse-phase HPLC and mass spectrometry
was >90%. The characteristics of the other peptides that were
used in this study are listed in Table 1. The peptides were
synthesized by standard solid-phase peptide synthesis and
delivered with a purity >95%.
2.2. Synthesis of Peptide−Polymer Conjugates.
2.2.1. Synthesis of OVA and HPV Peptide-ATRP Macro-
initiator. The synthesis of the OVA and HPV peptide-ATRP
macroinitiator is shown in Scheme 1. Resin-protected peptides
(OVA250−264 or HPV16 E743−57) with deprotected N-terminus
(equal to 0.1 mmol of the peptide) was dispersed in and
washed three times with 5 mL of dried dichloromethane. Next,
the resin was washed three times with 5 mL of NMP.
Subsequently, 3 equiv of DIPEA and 2 equiv of 2-bromo-
isobutyryl bromide (relative to −NH2 groups) in NMP were
added. The reaction mixture was stirred for 16 h at room
temperature. The Kaiser test36 was done to determine
nonreacted free amines, and when this test was negative, the
reaction was considered completed. The peptide-initiator was
deprotected and cleaved from the resin as follows. First, the
resin washed three times with NMP and subsequently a
solution of TFA/water/triisopropylsilan (95/2.5/2.5 v/v/v %)
was added and incubated for 4 h at room temperature under
vigorous shaking to fully deprotect the peptide. Next, the
peptide-initiator product was precipitated in a cold MTBE/n-
hexane (1/1; v/v %), separated, and washed two times with
MTBE/n-hexane using centrifugation (3000 × g, 5 min, 4 °C).
The obtained product was dispersed in water and freeze-dried
using a Christ “Alpha 1−2” freeze-dryer (Osterode, Germany).
The molecular masses of the synthesized peptide-initiator was
determined by electrospray mass spectrometry.
2.2.2. Synthesis of OVA- and HPV-poly(NIPAm) and HPV-
poly(DMAm) Conjugates. The OVA250−264- and the HPV16
E743−57-poly(NIPAm) peptide−polymer conjugates, referred to
as OVA-pNIPAm and HPV-pNIPAm, and HPV16 E743−57-
poly(DMAm), referred as to HPV-pDMAm, were synthesized
using atom transfer radical polymerization (ATRP).37 The
polymerization reaction is shown in Scheme 2.
The peptide macroinitiator (20 μmol) was dissolved in 2 mL
of water/ACN (80:20 v/v %) in a screw-capped septum vial. In
case of OVA250−264, the peptide was first dissolved in an alkaline
solution (pH 12), and subsequently, the pH was adjusted to pH
8.5 with HCl (0.5 M). In another screw-capped septum vial, 15
μmol of CuBr, 0.05 μmol of CuBr2, and 5.3 mmol (600 mg) of
NIPAm or 525 mg of DMAm were dissolved in 3 mL of water/
ACN (80:20 v/v %). The vials were capped with a septum and
the solutions were flushed with N2. Next, the peptide solution
was added to the NIPAm or DMAm solution, flushed with N2,
and placed in an ice bath, under rapid stirring. The
polymerization was initiated by adding 0.1 mL of 0.4 M
Me6TREN solution in water (degassed by flushing with N2
prior to addition), which immediately turned the reaction
mixture blue. Periodically, 50 μL samples were taken, diluted in
air-saturated D2O, and analyzed by
1H NMR to determine the
NIPAm or DMAm conversion.37 When the conversion was
∼70%, the reaction was stopped by flushing air into the
reaction mixture. The crude product was dialyzed (with dialysis
cassettes of 3000 kDa MWCO) against water at 4 °C for 2 days
and subsequently lyophilized. The peptide−polymer conjugates
were characterized by gel permeation chromatography (GPC)
using Mixed-D columns (Polymer Laboratories), a solution of
10 mM LiCl in DMF as eluent, a flow of 0.7 mL/min, and a
temperature of 40 °C. A refractive index detector was used, and
PEG standards were used for calibration.
2.2.3. Formulation Preparation of Self-Assembling Pep-
tide−Epitope (SAPE) Vaccines. 2.2.3.1. Peptide−Peptide
Vaccines. All peptide formulations indicated in Table 1 (except
OVA-SA peptide) were prepared as follows. One milligram of
the peptide was hydrated with 40 μL of 0.2 M NaOH solution,
and subsequently, phosphate buffered saline (PBS, 140 mM
NaCl, 13 mM Na2HPO4, and 2.5 mM NaH2PO4, pH 7.4) was
added in 200 μL portions up to 1 mL. After each step, the
peptide dispersion was sonicated in a water bath sonicator
(Fisher Scientific, Loughborough, UK) for 3 min at 30 °C.
Before reaching to final volume, the pH was adjusted to pH 7.4
by dropwise adding 0.2 M HCl. To prepare the OVA-SA
peptide formulation, one milligram of this peptide was
dissolved in 200 μL of HFIP. After solvent evaporation, the
obtained peptide film was hydrated in 40 μL of 0.2 M NaOH,
Scheme 1. Synthesis of ATRP Peptide Macroinitiator
Scheme 2. Polymerization Reaction of (a) NIPAm and (b) DMAm Using the Peptide Macroinitiator
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and then similar to other peptide preparations, 1 mL of PBS
(140 mM NaCl, 13 mM Na2HPO4, and 2.5 mM NaH2PO4, pH
7.4) was added in 200 μL portions. After pH adjustment, some
of the peptide formulations were supplemented with CpG (20
μg per injection; 10 μL of a 2 mg/mL of a stock solution of
CpG in PBS) as an adjuvant (Table 2).
2.2.3.2. Peptide−Polymer Vaccines. Peptide-pNIPAm for-
mulations were prepared by either a rapid heating38 or a heat
shock39 procedure. First, the thermosensitive peptide−
pNIPAm conjugates and nonthermosensitive peptide-
pDMAm, as a nonself-assembling peptide−polymer conjugate,
were dissolved in 10 mM PBS or 20 mM HEPES at room
temperature. Subsequently, some of the formulations were
supplemented with CpG (20 μg per injection; 10 μL of 2 mg/
mL stock solution of CpG in PBS), as an adjuvant (Table 2).
For the heat shock procedure, 100 μL of polymer solution (1
mg/mL) with or without CpG was added to 900 μL of PBS or
HEPES heated at 50 °C. Next, the self-assembled nanostruc-
tures were equilibrated at 37 °C for at least 5 min before being
analyzed for their physicochemical properties. For the rapid
heating procedure, an aqueous polymer solution (1−10 mg/mL
in PBS or HEPES) was rapidly heated at 50 °C and kept at this
temperature for 5 min. Subsequently, the formed nano-
assemblies were cooled down to 37 °C until further analysis.
2.2.4. Characterization of SAPEs. 2.2.4.1. Critical Aggre-
gation Concentration Determination. The critical aggregation
concentration (CAC) of the OVA-SA and HPV-SA vaccines
was determined using the Nile red assay as described by Zhang
et al.40 In short, peptide-based SAPEs were dissolved in PBS
(pH 7.4) in concentrations ranging from 0.1 to 500 μg/mL.
Next, 200 μL of each dilution was spiked with 0.2 μL of Nile
red solution (1.25 mM in ethanol). After overnight incubation
at room temperature, fluorescence emission (Ex550/Em635)
was measured by a Horiba fluorolog fluorometer (Horiba Jobin
Yvon, Longjumeau Cedex, France). The fluorescence intensity
at 635 nm was plotted against the logarithm of peptide
concentrations to determine the CAC. The point of
intersection of two linear fits of the plot was considered as
the CAC value. The CAC of OVA-pNIPAm and HPV-
pNIPAm vaccines was determined by dynamic light scattering
(DLS, Malvern Instruments, Malvern, U.K.). In detail, peptide-
pNIPAm conjugates were dissolved in PBS (pH 7.4) in
concentrations ranging from 1 to 1000 μg/mL. The
thermosensitive SPAEs (peptide-pNIPAm) were formed by
the rapid heating method, as described above. The Z-average
diameter (Zave, nm) and light scattering intensity (LSI) of the
SAPE dispersion were monitored by DLS at 37 °C. The LSI
was plotted against the logarithm of the conjugate concen-
trations, and the point of intersection of two linear fits of the
plot was considered as the CAC of the peptide-pNIPAm
SAPEs.
2.2.4.2. Particle Size and Zeta Potential Measurement.
The prepared SAPE particles in PBS (pH 7.4) were sized using
an ALV CGS-3 goniometer system (Malvern Instruments,
Malvern, U.K.) equipped with a JDS Uniphase 22 mW He−Ne
laser operating at 632.8 nm, an optical fiber-based detector, a
digital LV/LSE-5003 correlator. and a temperature controller
(Julabo water bath). The DLS time correlation was analyzed by
ALV Correlator 3.0 software (ALV, Langen, Germany). Zeta
potential measurement of the peptide particles was performed
in 10 mM HEPES, pH 7.0, at 25 °C for the peptide−peptide
and 37 °C for the peptide-pNIPAm assemblies using a Malvern
Zetasizer Nano-Z (Malvern Instruments, Malvern, U.K.) with
universal ZEN 1002 “dip” cells and DTS (Nano) software
(version 4.20). DTS 1235 latex beads (Zeta Potential Transfer
Standard, Malvern Instruments, Malvern, U.K.) were used for
calibration.
2.2.4.3. Particle Morphology. The morphology and size of
the peptide-pNIPAm SAPEs were visualized by transmission
electron microscopy (TEM). Briefly, samples (0.1 mg/mL in
HEPES 10 mM) were soaked onto prewarmed carbon-coated
copper grids for 2 min, and excess liquid was removed by a
filter paper. The grids were subjected to negative staining with
2% uranyl acetate (Merck, Germany) for 45 s and dried for 10
min at room temperature before acquisition of TEM images
(Tecnai 10, Philips, The Netherlands). Atomic force micros-
copy (AFM) was applied to visualize the morphology of the
peptide-based vaccines. Briefly, 40 μL of a 0.02% (w/v)
polylysine solution in water was placed on a freshly cleaved
mica substrate and, after 5 min incubation, washed with filtered
Milli-Q water followed by drying under N2 flow. Next, 30 μL of
the sample was loaded on the treated mica and incubated for 1
min, followed by washing three times with 20 μL of filtrated
Milli-Q water to discharge nonattached particles and salts.
Finally, the prepared sample was dried by an N2 flow. ScanAsyst
image mode was used at room temperature with a Digital
Instruments NanoScope V, equipped with silicon nitride
cantilevers (Veeco, NY, USA). Images were analyzed by
NanoScope Analysis 1.40 software. Several images were taken
at different days of individually prepared samples.
2.2.4.4. Circular Dichroism. Circular dichroism spectra were
obtained by a double beam DSM 1000 CD spectrometer
Table 2. List of Vaccine Formulations Used for Immunization Studies
groups
in vivo experiment 1 2 3 4 5 6 7
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aThe dose of antigen in OVA-SA, OVA-pNIPAm, and OVA peptide was 40 nmol/injection (concentration: 200 μM). bThe dose of antigen in HPV-
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(Online Instrument Systems, Bogart, GA, USA) using quartz
cuvettes with different path length appropriate for the different
concentrations. Samples of peptide-based SAPEs (at concen-
tration of 200 mM OVA-SA and 300 mM HPV-SA) were
prepared in PBS (pH 7.4, 140 mM NaCl). Five measurements
at 25 °C using 1 nm intervals and 1 nm bandwidth at a
wavelength range from 185−250 nm were performed. Next, the
spectrum of the buffer was subtracted from the averaged
spectrum of the samples. To normalize for concentration, the
results are presented as molar ellipticity.
2.2.5. Cell Lines. TC-1 cells were derived from primary lung
epithelial cells of C57BL/6 mice cotransformed with HPV-16
E6 and E7 and c-Ha-ras oncogenes.41 These cells were cultured
at 37 °C with 5% CO2 in IMDM, supplemented with 8% fetal
calf serum (FCS) (Greiner), 400 μg/mL of Geneticin (G418)
(Life Technology), 2 mM L-glutamine, 1 mM sodium pyruvate,
2 mM nonessential amino acid, and 100 IU/mL penicillin.42
2.2.6. In Vivo MHC Class I-Restricted Antigen Presentation
with OVA SAPEs. To establish antigen presentation in vivo,
CD8+ T cells were isolated from spleen and lymph nodes of
CD90.1 OT-I mice. T cells were enriched using the CD8+
enrichment kit according to manufacturer’s protocol (BD
Bioscience), and 500,000 cells were injected intravenously into
the tail vein of CD90.2 mice (n = 5/group). One day later, mice
were vaccinated via subcutaneous (s.c.) injection with self-
assembled or soluble peptide constructs containing OVA CTL
epitopes (40 nmol/injection) (Table 2). Peripheral blood
mononuclear cells (PBMCs) were collected at days 3, 5, 7, and
10 after immunization to analyze the expansion of the
transferred OVA-specific T cells caused by cross presentation
of the OVA antigen. After lysis of red blood cells, T cells were
stained with fluorescently labeled antibodies for CD8α and the
OT-I congenic marker CD90.1 (Thy1.1) and analyzed by flow
cytometry. T cell expansion is expressed as the number of
transferred (OT-I) T cells as a percentage of total CD8+ T cells.
2.2.7. Endogenous CD8+ T Cell Activation. To evaluate the
potency of the SAPE vaccines to induce endogenous specific
CD8+ T cells, naiv̈e C57BL/6 mice (n = 5) were s.c. vaccinated
in the right flank with the indicated formulations in Table 2.
After 14 days, the mice received a booster injection. PBMCs
were collected 10 days after prime vaccination and 5 and 7 days
after the boost vaccination. To quantify antigen-specific CD8+
T cells by flow cytometry, after lysis of red blood cells, T cells
were stained with CD8α and H-2Db E749−57 APC tetramer for
HPV vaccines.
2.2.8. Therapeutic Vaccination in Mice with Established
Tumor. Groups of mice (n = 12) were challenged in the right
flank with 100,000 TC-1 tumor cells. At day 7, when the
tumors were palpable (tumor size between 0.5 and 10 mm3),
mice were s.c. vaccinated with the vaccine formulations (Table
2). Mice received a booster immunization 14 days after prime
vaccination. Tumor size was measured two-dimensionally with
calipers 2−3 times per week and followed for approximately 35
days.43
Mice were sacrificed for ethical reasons when the actual
tumor volume reached about 2000 mm3 or when the tumor
became ulcerated. Before and after booster vaccination, blood
samples were collected via tail vein in heparinized tubes for
detecting HPV-specific CD8+ T by flow cytometry.
2.2.9. Statistical Analysis. Data were analyzed using
GraphPad Prism 5.02 software. For tumor experiments,
Kaplan−Meier survival curves were applied, and the differences
between survival curves were analyzed by log-rank test (p <
0.05 was considered statistically significant). Expansion of
antigen-specific CD8+ T cells in the blood of immunized mice
after booster vaccination with the SAPE vaccines was compared
to control mice by student t test. The percentage of OT-I cells
on day 5 postimmunization in mice treated with SAPE vaccines
was compared to control group by student t test.
3. RESULTS AND DISCUSSION
3.1. Design of Peptide-Based SAPEs. The SA2 peptide
was previously designed and studied in depth as a self-
assembling peptide forming nanovesicles in aqueous solu-
tions.29 In the present study, we have exploited the capacity of
SA2 hydrophobic domain (SA: Ac-AAVVLLLW-COOH) to
form nanostructures once conjugated to antigen epitopes. To
this end, peptides (OVA250−264 (SGLEQLESIINFEKL) derived
from chicken ovalbumin and containing the H2b restricted
MHC class I peptide epitope SIINFEKL, and HPV743−57
(GQAEPDRAHYNIVTF) derived from human papillomavirus
E7 protein and containing the H2b restricted MHC class I
peptide epitope RAHYNIVTF) were fused to the C-terminus
of the SA domain (OVA-SA and HPV-SA, Table 1). In the
selected HPV743−57 and OVA250−264 peptides, the presence of
the natural flanking amino acids, GQAEPD at the N-terminus
of the HPV and SGLEQLE at the N-terminus of OVA CTL
epitopes, allows proper cleavage and processing of the peptides
in DCs.44,45
3.2. Synthesis and Characterization of Peptide-
pNIPAm and -pDMAm Conjugates. The OVA and HPV
peptide macroinitiators were synthesized by coupling an ATRP
initiator to the N-terminus of the peptides (Scheme 1). The
molecular masses of the peptide-initiators were determined
using an electron spray mass spectrometer, and this analysis
showed that the ATRP initiator was coupled to the N-terminus
of the peptides (data not shown). OVA-pNIPAm, HPV-
pNIPAm, and HPV-pDMAm peptide−polymer conjugates
were synthesized by ATRP using NIPAm and DMAm, as the
monomer and the peptide macroinitiators (Scheme 2). The
structures of the synthesized polymers were confirmed by 1H
NMR spectroscopy. Table 3 summarizes the molecular
characteristics of the synthesized polymers. The resulting
OVA-pNIPAm and HPV-pNIPAm peptide−polymer conju-
gates have pNIPAm block length ofMn ≈ 30,000 and 40 000 g/
mol and a fixed peptide molecular weight of 1719 g/mol
(OVA) and 1717 g/mol (HPV), respectively. The HPV-
pDMAm peptide polymer conjugate had also Mn ≈ 30 000 g/
mol, similar to the peptide-pNIPAm conjugates. ATRP was
used for the synthesis of the peptide-pDMAm and peptide-
pNIPAm conjugates since this is an efficient polymerization
technique, especially for acrylamides, and results in polymers
with a very low polydispersity.46,47 The synthesized peptide-
pNIPAm and peptide-pDMAm conjugates had an average
molecular weight close to the target value and a very low
Table 3. Characteristics of Peptide-pNIPAm Conjugates




OVA-pNIPAm 28,400 33,600 1.18
HPV-pNIPAm 38,900 42,100 1.08
HPV-pDMAm 29,500 35,100 1.19
aMn = number-average molar weight (g/mol) and Mw = weight-
average molar weight (g/mol) as determined by GPC.
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polydispersity. It has been shown that pNIPAm is a
thermosensitive polymer with an LCST around 33 °C in
aqueous solution.48 Consequently, it is expected that peptide-
pNIPAm conjugate can form self-assemblies with a hydrophilic
peptide shell and a hydrophobic pNIPAm core above the LCST
of the pNIPAm blocks as first described for PEG-pNIPAm.49
However, pDMAm is a nonthermosensitive/fully water-soluble
polymer, and the resulting peptide-pDMAm conjugate does,
therefore, not self-assemble into nanoparticles and was used as
a control formulation in the in vivo tumor experiments.
3.3. Characterization of Self-Assembling Peptide
Epitopes (SAPEs). To characterize the peptide nanostructures,
several complementary methods were applied (Table 4). In
peptide based systems, similar to the previously reported SA2
peptide, amphiphilic peptide epitopes self-assembled into
discrete nanostructures above a threshold concentration, the
critical aggregation concentration (CAC). The CAC values of
the OVA-SA and HPV-SA vaccines were both ca. 15 μM, which
is in the same range as that of SA2,29 and indicate that the
peptide epitope sequences appended to the C-terminus of the
self-assembling SA domain had marginal influence on the
CAC.29
AFM revealed that OVA-SA particles had a spherical
morphology with similar particle size as measured by DLS
(Figure 1). The obtained HPV-SA nanoparticles were also
analyzed at concentrations used for the in vivo experiments
(300 μM), which showed consistent characteristics regarding
size and morphology. DLS for the HPV-SA peptide revealed
that self-assembling peptide formed nanostructures with a mean
hydrodynamic diameter of 85 nm and a PDI of 0.4 (Table 4).
AFM analysis of the immobilized nanostructures on mica
revealed toroidal structures with a diameter of ∼100 nm in
accordance with the size obtained by DLS (Figure 1). The
observed concave structures may suggest a hollow, vesicular
nature of these nanostructures, similar to the vesicular
structures formed by the previously reported SA2 peptide.30
Although the CAC for the different SA based peptides were
dictated by the SA tag, the morphology of the nanoparticles,
however, was affected by the appended peptide epitope
sequences. Negative zeta potential was seen for both SAPEs
at pH 7.4. The isoelectric point (pI) of the OVA and HPV
peptides are 4.1 and 5.7, respectively,50 and therefore, they bear
negative charge at pH 7.4.
The previous study on SA2 peptide demonstrated the ability
of this peptide to form a stable beta-sheet structure once
integrated into self-assemblies.29 However, comparison be-
tween the secondary structures of HPV-SA and OVA-SA with
SA2 above their CACs can be indicative in similarity or
dissimilarity of self-assembling pathways in these series of
peptides. The CD spectrum of the HPV-SA and OVA-SA
nanostructures showed a negative peak between 210 and 220
nm (Figure S1) that is typical for peptides forming β-sheets.51
This result is in accordance with the obtained secondary
structure of previously studied SA2 peptide.29
Peptide-pNIPAm (OVA and HPV) SAPEs prepared by rapid
heating in PBS were characterized for their morphology, size,
polydispersity, and zeta potential (Table 4). OVA-pNIPAm and
HPV-pNIPAm SAPEs had a mean hydrodynamic diameter of
115 and 196 nm, respectively, with a narrow size distribution
(Table 4). TEM analysis showed spherical particles of 20−80
nm for both OVA-pNIPAm and HPV-pNIPAm SAPEs (Figure
2) but no particles for HPV-pDMAm conjugate. The mean
hydrodynamic diameters of all nanoparticle formulations,
determined by TEM, were smaller than those determined by
DLS. In a nonmonodisperse particle suspension, the mean
hydrodynamic diameter of the particles might be overestimated
by DLS measurement because of the presence of large particles
or small aggregates.52,53 TEM analysis of SAPE nanostructures
demonstrates that the majority of the particles are in a range of
20−50 nm. However, there are a few larger particles of 200−
500 nm, which affect the actual average particle size of SAPE
nanostructures as measured by DLS. Zeta potential analysis of
the peptide-pNIPAm nanoparticles showed a negative zeta
potential for both nanoparticles at pH 7.4 (Table 4), which
indicates the presence of negatively charged OVA or HPV
peptide at the surface of the nanoparticles at pH 7.4. From all
these results, it can be concluded that these amphiphilic peptide
polymer conjugates mainly form micelles. The CAC of OVA-
pNIPAm and HPV-pNIPAm SAPEs was ∼0.02 mg/mL,
comparable to those of other amphiphilic pNIPAM block
copolymers.54 Preparation of the peptide-pNIPAm nano-
particles was relatively easy because of the hydrophilicity of
pNIPAm at ambient temperature (below the LCST of
pNIPAm, 33 °C), which allows dissolution of the peptide-
pNIPAm conjugates in an aqueous solution and at room
temperature. Next, rapid heating of this solution resulted in
small and relatively uniform nanoparticles with a narrow size
distribution due to dehydration and self-assembling of the
pNIPAm part of the conjugate.
3.4. In Vivo Antigen Cross-Presentation. To assess the T
cell activation capacity of the SAPEs in vivo, OVA-specific CD8+
T cells (OT-I) were injected into C57BL/6 mice 1 day before
administration of OVA containing SAPEs. In this way, the
precursor frequency of OVA-specific T cells was artificially
elevated to high levels, thereby facilitating the read-out of in
vivo antigen processing and presentation and enabling the
detection of subtle differences between vaccine formulations in
terms of (cross-)presentation of the OVA antigens. The degree
of OT-I T cells expansion as a consequence of in vivo (cross-
)presentation of the OVA antigens at various time points after
vaccination is shown in Figure 3. High numbers of OT-I cells
were observed in the blood samples peaking at day 5 after
vaccination with both SAPE vaccines (OVA-SA and pNIPAm-
OVA) adjuvanted with CpG, which proved stronger to the
administration of the OVA250−264 peptide with CpG (Figure 3)
(p < 0.05 for pNIPAm-OVA). The strong expansion of OT-I
cells indicated the capacity of these designed vaccines for cross-
presentation, which is necessary for effective induction of
cellular immunity.55 These results clearly show that SAPE
Table 4. Characteristics of the Self-Assembling Peptides
















OVA-pNIPAm 115 ± 3
/0.10 ± 0.02
−19 ± 1
HPV-pNIPAm 196 ± 2
/0.07 ± 0.03
−16 ± 2
aMeasurement was performed by dynamic light scattering. bAll
measurements were repeated three times.
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formulations adjuvanted with CpG are efficiently processed in
vivo leading to T cell activation.
3.5. Endogenous Specific CD8+ T Cell Activation. The
development of strong functional CD8+ T cells is a necessity
for robust antitumor immunity. As the HPV SAPEs were
further evaluated in vivo for antitumor efficacy, the
immunostimulatory potential of the HPV vaccines were
investigated for induction of an endogenous T cell response
by s.c. injection of formulated SAPEs in a prime-boost regimen
into naiv̈e C57BL/6 mice (Table 2). Ten days after prime
Figure 1. AFM images of (a) OVA-SA and (b) HPV-SA peptides self-assemblies immobilized on poly-L-lysine coated mica.
Figure 2. TEM pictures of nanoparticles composed of (a) HPV-pNIPAm and (b) OVA-pNIPAm SAPEs.
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injection and 5 and 7 days after the booster, the induction of
specific HPV CD8+ T cells in the collected blood samples was
analyzed using tetramer staining.
For both adjuvanted SAPEs (HPV-SA and HPV-pNIPAm),
as shown in Figure 4, the nanoassemblies were able to induce
significantly higher HPV-specific CD8+ T cell response in mice
after booster vaccination, as compared to the control groups (p
< 0.001). The response increased from day 5 to 7 after booster
immunization (p < 0.001). However, after prime immunization,
the mice showed weak immune responses. Thus, for such
peptide vaccines, not only an adjuvant is necessary to induce a
strong immune response but also a booster vaccination is
important to induce strong immunity and antigen-specific
memory T cells.42
In general, therapeutic cancer vaccines aim to raise the
number of antigen-specific CD8+ cytotoxic T lymphocyte
cells.56−58 Our experiments show efficient endogenous CD8+ T
cell activation (HPV vaccines) indicating that these designed
vaccines enable effective cross-presentation, which is obligatory
for induction of cellular immunity.59 Our results also point out
that the adjuvant and particulate system have a complementary
effect to induce efficient immune responses, in agreement with
other studies.60 It has been reported that CpG enhanced
antigen cross-presentation and improved CD8+ T cell
responses.61,62 The effect of ODNs containing unmethylated
cytosine-guanine (CpG) motifs as toll-like receptor 9 (TLR-9)
agonist on cellular immunity has been associated with its ability
to induce and expand the number of activated DCs. In addition,
it can elevate the expansion of antigen-stimulated T cells by
inhibition of activation-induced cell death.63,64 Therefore,
codelivery of efficient adjuvants such as toll-like receptor
ligands with the SAPEs can improve the efficiency of such
formulations.65,66 Interestingly, several peptide-based toll-like
receptor ligands exist (such as RS01, Gln-Glu-Ile-Asn-Ser-Ser-
Tyr; RS09, Ala-Pro-Pro-His-Ala-Leu-Ser) that can be exploited
for incorporation into SAPEs to improve CTL responses.67
Codelivery of antigen and adjuvant does not only result in
proper DC activation and antigen presentation, but it also
significantly lowers systemic toxicity due to reduced systemic
exposure.68,69
3.6. Tumor Control in Mice Treated with HPV
Vaccines. To investigate the potential antitumor efficacy of
HPV SAPE vaccines in a mouse model of HPV-related cancer,
naiv̈e mice were s.c. inoculated with TC-1 tumor cells
expressing HPV16 oncogenes E6 and E7. Seven days after
tumor inoculation (when the tumors were palpable), the
treatment group received HPV SAPE vaccines adjuvanted with
CpG in a prime-boost regimen. In addition, one group of mice
was vaccinated with soluble HPV16 E743−57 peptide, without a
self-assembling domain, +CpG. As negative controls, one group
did not receive any formulation, and one group was treated
with HPV-pDMAm + CpG, a similar structure as HPV-
pNIPAm, without SAPE forming capacities. Tumor size was
monitored over time, and the proportions of mice with a tumor
size not exceeding the humane end point (tumor size of 2000
mm3) are presented in a Kaplan−Meier plot (Figure 5). Both
HPV SAPE vaccines adjuvanted with CpG strongly delayed the
tumor growth and significantly prolonged the overall survival of
mice compared with untreated mice (p < 0.0005 for HPV-
pNIPAm + CpG and p < 0.05 for HPV-SA + CpG).
Importantly, the HPV-pDMAm vaccine did not delay tumor
outgrowth, indicating that self-assembly into nanostructures is
crucial for efficient vaccine function, and merely elongating the
Figure 3. In vivo (cross)-presentation of OVA antigen to OVA-specific
CD8+ (OT-I) T cells. The percentage of OT-I cells relative to the total
number of CD8+ T cells in PMBCs of the mice vaccinated with 200 μL
of indicated peptide formulations (equal to 40 nmol of OVA peptide/
injection) on days 2, 5, 7, and 9 postimmunization. N = 5 mice per
group, representative of two experiments. The percentage of OT-I
cells on day 5 postimmunization in mice treated with OVA-SA + CpG
and OVA-pNIPAm + CpG vaccines is compared to that of soluble
OVA peptide + CpG. Statistical significance of the compared groups is
calculated by student’s t test. N = 5 mice per group, and data are
presented as mean ± SE.
Figure 4. Percentage of endogenous HPV 16 E749−57-specific CD8
+ T
cells in peripheral blood of mice vaccinated with indicated
formulations (equal to 60 nmol of HPV peptide per injection) 10
days after prime vaccination and 6 or 7 days after booster vaccination.
HPV-SA + CpG was tested in a different experiment thus presented
separately because of different background (untreated mice) in FACS
analysis. HPV-specific CD8+T cell expansion after booster vaccination
in mice treated with HPV-SA + CpG and HPV-pNIPAm + CpG
vaccines is compared to untreated mice and/or soluble HPV peptide +
CpG. Statistical significance of the compared groups is calculated by
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peptide by attaching a long polymer chain did not enhance T
cell activating properties.70 Moreover, development of HPV-
associated tumors was not delayed by injection of only HPV16
E743−57 peptide + CpG, emphasizing the need for nanoparticle
formation of the peptide vaccine for efficient T cell priming,
delaying tumor growth. These results are strongly indicative
that the expansion of antigen−specific T cells is associated with
the particulate form of peptide vaccines, while the soluble form
of peptide vaccine is not effective at all.
Based on these results, it can be concluded that the soluble
form of the peptide vaccine even with a strong adjuvant is not
effective. However, in the form of a particular structure, it is
efficiently processed and presented by DCs to activate effector
T cells that delay the tumor growth.
It has been shown that peptide vaccines offer a promising
approach to raising specific humoral or cellular immune
responses against cancer cells.71 Various studies proposed to
deliver peptide vaccines in a particulate form, which favors
innate immune recognition and activation.72,73 Only a few
studies explored peptide self-assembly as a means to present
peptide epitopes in a particulate form to the immune system.
For example, Collier and co-workers produced a nanofiber
vaccine by incorporating a fiberizing self-assembling peptide
into the structure of a peptide antigen.74 They showed that the
self-assembling peptide epitope triggered the formation of high-
levels of IgG1, IgG2a, and IgG3 antibodies against the attached
antigen epitope.74 Most other studies used long stretches of
amino acids to drive peptide self-assembly, which impedes solid
phase peptide synthesis.75−78 In addition, it also increases the
risk of immunogenicity against the carrier part.79 In this study,
we demonstrated that by attaching an eight amino acid peptide
sequence or a thermosensitive polymer tail to antigenic peptide
epitopes with different length and composition, discrete
nanostructures could be generated in a reproducible fashion.
This strategy can overcome some shortages of other particulate
systems. Besides the ease of production and well-defined
formulation, several studies indicated a correlation between
epitope density and immune responses.80−82 In the designed
SAPEs, the generated particles comprise a high density of
antigenic epitopes displayed on the surface of nanoparticles,
while in several studied polymeric nanoparticles the reported
peptide loading was on the average <5%.83,84
Our in vivo results have shown that relatively short HPV
peptides in particulate forms are able to significantly delay the
tumor growth but did not cause complete tumor regression,
and this is in agreement with previous studies.35,45 In a study,
we evaluated the antitumor efficacy of a synthetic long peptide
(SLP) covering HPV peptide encapsulated in polymeric
nanoparticles (NPs) in a therapeutic tumor model.45 Similar
to the results described here we showed that the peptide
vaccine in the particulate form without adjuvant (Poly I:C) did
not significantly delay tumor growth or prolong the survival of
mice in comparison with untreated mice. Interestingly, peptide-
loaded nanoparticles with poly I:C (encapsulated or soluble)
significantly prolonged the survival of mice compared to the
untreated group. Although there are differences between the
two studies in the experimental settings, such as the nature of
the particulate carrier, type, and dosage of the adjuvants and
length of HPV peptide vaccines, similar results in antitumor
efficacy for the adjuvanted particulate systems in both studies
were observed. These findings support our hypothesis that by
simply extending the peptide epitopes with a self-assembling
segment, a particulate antigen-delivery system can be
established without laborious processing and formulation steps.
4. CONCLUSION
We conclude that nanoparticle formation based on the
introduced self-assembling materials for peptide vaccines can
be an attractive approach and simple alternative for other
particulate systems. The extension of minimal epitopes by a
self-assembling segment can efficiently augment the induction
of a desired immune response: first, by risk reduction of T cell
anergy since the segments have to be processed by DCs to
release the minimal epitopes; second, by enhancing cellular
uptake of particulate vaccines and antigen-specific T cell
response. The described approach exploits the advantages of
self-assembling peptide epitopes to improve tumor-specific T
cell response for cancer treatment.
In conclusion, this study demonstrates that self-assembling
peptide−peptide and peptide−polymer conjugates are attrac-
tive systems for molecularly well-defined vaccines.
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(34) de Graaf, A. J.; Azevedo Prośpero dos Santos, I. I.; Pieters, E. H.
E.; Rijkers, D. T. S.; van Nostrum, C. F.; Vermonden, T.; Kok, R. J.;
Hennink, W. E.; Mastrobattista, E. A Micelle-Shedding Thermosensi-
tive Hydrogel as Sustained Release Formulation. J. Controlled Release
2012, 162 (3), 582−590.
(35) Zwaveling, S.; Mota, S. C. F.; Nouta, J.; Johnson, M.; Lipford, G.
B.; Offringa, R.; Van der Burg, S. H.; Melief, C. J. M. Established
Human Papillomavirus Type 16-Expressing Tumors Are Effectively
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.6b01003
Mol. Pharmaceutics 2017, 14, 1482−1493
1491
Eradicated Following Vaccination with Long Peptides. J. Immunol.
2002, 169 (1), 350−358.
(36) Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color
Test for Detection of Free Terminal Amino Groups in the Solid-Phase
Synthesis of Peptides. Anal. Biochem. 1970, 34 (2), 595−598.
(37) De Graaf, A. J.; Boere, K. W. M.; Kemmink, J.; Fokkink, R. G.;
Van Nostrum, C. F.; Rijkers, D. T. S.; Van Der Gucht, J.; Wienk, H.;
Baldus, M.; Mastrobattista, E.; Vermonden, T.; Hennink, W. E.
Looped Structure of Flowerlike Micelles Revealed by 1H NMR
Relaxometry and Light Scattering. Langmuir 2011, 27 (16), 9843−
9848.
(38) Rijcken, C. J.; Snel, C. J.; Schiffelers, R. M.; van Nostrum, C. F.;
Hennink, W. E. Hydrolysable Core-Crosslinked Thermosensitive
Polymeric Micelles: Synthesis, Characterisation and in Vivo Studies.
Biomaterials 2007, 28 (36), 5581−5593.
(39) Neradovic, D.; Soga, O.; Van Nostrum, C. F.; Hennink, W. E.
The Effect of the Processing and Formulation Parameters on the Size
of Nanoparticles Based on Block Copolymers of Poly(ethylene
Glycol) and poly(N-Isopropylacrylamide) with and without Hydro-
lytically Sensitive Groups. Biomaterials 2004, 25 (12), 2409−2418.
(40) Zhang, A.; Zhang, Z.; Shi, F.; Ding, J.; Xiao, C.; Zhuang, X.; He,
C.; Chen, L.; Chen, X. Disulfide Crosslinked PEGylated Starch
Micelles as Efficient Intracellular Drug Delivery Platforms. Soft Matter
2013, 9 (7), 2224−2233.
(41) Lin, K. Y.; Guarnieri, F. G.; Staveley-O’Carroll, K. F.; Levitsky,
H. I.; August, J. T.; Pardoll, D. M.; Wu, T. C. Treatment of Established
Tumors with a Novel Vaccine That Enhances Major Histocompati-
bility Class II Presentation of Tumor Antigen. Cancer Res. 1996, 56
(1), 21−26.
(42) Van Duikeren, S.; Fransen, M. F.; Redeker, A.; Wieles, B.;
Platenburg, G.; Krebber, W.-J.; Ossendorp, F.; Melief, C. J. M.; Arens,
R. Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict
Therapeutic Efficacy against Tumors. J. Immunol. 2012, 189 (7),
3397−3403.
(43) Li, M.; Zhang, Y.; Liu, Z.; Bharadwaj, U.; Wang, H.; Wang, X.;
Zhang, S.; Liuzzi, J. P.; Chang, S.-M.; Cousins, R. J.; Fisher, W. E.;
Brunicardi, F. C.; Logsdon, C. D.; Chen, C.; Yao, Q. Aberrant
Expression of Zinc Transporter ZIP4 (SLC39A4) Significantly
Contributes to Human Pancreatic Cancer Pathogenesis and
Progression. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (47), 18636−
18641.
(44) Welters, M. J. P.; Bijker, M. S.; van den Eeden, S. J. F.; Franken,
K. L. M. C.; Melief, C. J. M.; Offringa, R.; van der Burg, S. H. Multiple
CD4 and CD8 T-Cell Activation Parameters Predict Vaccine Efficacy
in Vivo Mediated by Individual DC-Activating Agonists. Vaccine 2007,
25 (8), 1379−1389.
(45) Rahimian, S.; Fransen, M. F.; Kleinovink, J. W.; Christensen, J.
R.; Amidi, M.; Hennink, W. E.; Ossendorp, F. Polymeric Nano-
particles for Co-Delivery of Synthetic Long Peptide Antigen and Poly
IC as Therapeutic Cancer Vaccine Formulation. J. Controlled Release
2015, 203, 16−22.
(46) Sumerlin, B. S. Proteins as Initiators of Controlled Radical
Polymerization: Grafting-from via ATRP and RAFT. ACS Macro Lett.
2012, 1 (1), 141−145.
(47) Averick, S.; Mehl, R. A.; Das, S. R.; Matyjaszewski, K. Well-
Defined Biohybrids Using Reversible-Deactivation Radical Polymer-
ization Procedures. J. Controlled Release 2015, 205, 45−57.
(48) Schild, H. G. Poly(N-Isopropylacrylamide): Experiment, Theory
and Application. Prog. Polym. Sci. 1992, 17 (2), 163−249.
(49) Topp, M. D. C.; Dijkstra, P. J.; Talsma, H.; Feijen, J.
Thermosensitive Micelle-Forming Block Copolymers of Poly(ethylene
Glycol) and Poly(N-Isopropylacrylamide). Macromolecules 1997, 30
(26), 8518−8520.
(50) Protein Calculator v3.4. http://protcalc.sourceforge.net/
(accessed Nov 2, 2016).
(51) Rudra, J. S.; Sun, T.; Bird, K. C.; Daniels, M. D.; Gasiorowski, J.
Z.; Chong, A. S.; Collier, J. H. Modulating Adaptive Immune
Responses to Peptide Self-Assemblies. ACS Nano 2012, 6 (2), 1557−
1564.
(52) Bootz, A.; Vogel, V.; Schubert, D.; Kreuter, J. Comparison of
Scanning Electron Microscopy, Dynamic Light Scattering and
Analytical Ultracentrifugation for the Sizing of Poly(butyl Cyanoacry-
late) Nanoparticles. Eur. J. Pharm. Biopharm. 2004, 57 (2), 369−375.
(53) Filipe, V.; Hawe, A.; Jiskoot, W. Critical Evaluation of
Nanoparticle Tracking Analysis (NTA) by NanoSight for the
Measurement of Nanoparticles and Protein Aggregates. Pharm. Res.
2010, 27 (5), 796−810.
(54) Klaikherd, A.; Nagamani, C.; Thayumanavan, S. Multi-Stimuli
Sensitive Amphiphilic Block Copolymer Assemblies. J. Am. Chem. Soc.
2009, 131 (13), 4830−4838.
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